NRx Pharmaceuticals, Inc.
NASDAQ:NRXPBiotechnology
+$0.06 today
- Market cap
- $113.04M
- Beta
- 2.19
- P/E (TTM)
- -5.3
- EPS (TTM)
- -$0.76
Volume 1.39M
Average 1.27M
Fair Value & DCF
Compare our fair value with your own assumptions
Intrinsic Alpha selects a valuation method suited to the business. Use the calculator below to build an independent scenario with your preferred cash-flow basis.
NRx Pharmaceuticals, Inc.
NASDAQ:NRXP
Intrinsic Alpha fair value
Locked
Current Price
$2.55
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Build your own valuation
Test an independent scenario and compare it with Intrinsic Alpha's estimate.
Sign in to use the DCF calculator
Free accounts get 5 valuations per week. Upgrade for more.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | N/A | +278.2% (5yr)1 analysts |
| Net Income | N/A | N/A | N/A | N/A1 analysts |
| EBIT | N/A | N/A | N/A | N/A1 analysts |
Analysis
Forward estimates point to Revenue at +278.2% (5yr), giving you a quick read on expected growth from here.
Estimates & History
Historical data and analyst estimates. Solid bars are actuals; dashed-border bars are future estimates.
Competitor Valuations
Peer stocks ranked by intrinsic value status
| Company | Market Cap | Price | Valuation | P/E | 1Y Return |
|---|---|---|---|---|---|
Century Therapeutics, Inc. NASDAQ:IPSC | $298.77M | $1.65 | Not rated | -1.8 | +169.00% |
Spruce Biosciences, Inc. NASDAQ:SPRB | $124.47M | $43.31 | Not rated | -1.9 | -60.54% |
Cue Biopharma, Inc. NASDAQ:CUE | $117.10M | $16.12 | Not rated | -6.7 | -13.07% |
Outlook Therapeutics, Inc. NASDAQ:OTLK | $100.54M | $0.41 | Not rated | -2.1 | -78.67% |
Equillium, Inc. NASDAQ:EQ | $81.80M | $1.29 | Not rated | -15.3 | +10.89% |
Werewolf Therapeutics, Inc. NASDAQ:HOWL | $47.64M | $0.98 | Not rated | -1.4 | +20.51% |
Coeptis Therapeutics, Inc. NASDAQ:COEP | $38.62M | $10.99 | Not rated | -8.3 | -10.24% |
Karyopharm Therapeutics Inc. NASDAQ:KPTI | $408,266.00 | $0.02 | Not rated | -1.0 | +21.70% |
Continue the stock analysis
Jump to another research area for this company.